An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm

Behavioural Pharmacology

Volumn 20, Issue 2, 2009, Pages 184-194

  Li, Ming ^a   He, Wei ^a   Mead, Alexa ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Antipsychotic drugs; Chlordiazepoxide; Conditioned avoidance response; Drug?drug conditioning; Polypharmacy; Psychotherapeutic drug?drug interaction; Rat; Schizophrenia

Indexed keywords

ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORDIAZEPOXIDE; HALOPERIDOL; NEUROLEPTIC AGENT; NEUROTRANSMITTER RECEPTOR; OLANZAPINE; BENZODIAZEPINE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; AVOIDANCE BEHAVIOR; CONDITIONING; DRUG DRUG CONDITIONING; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; INTEROCEPTIVE DRUG STATE MECHANISM; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY; REPEATED DRUG DOSE; SCHIZOPHRENIA; ANIMAL; DRUG INTERACTION; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BENZODIAZEPINES; CHLORDIAZEPOXIDE; CONDITIONING (PSYCHOLOGY); CUES; DRUG INTERACTIONS; HALOPERIDOL; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 66549130720     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e32832a8f66     Document Type: Article

References (57)

1. Alfaro CL (2001). Emerging role of drug interaction studies In drug development: the good, the bad, and the unknown. Psychopharmacol Bull 35:80-93.
2. Arnt J (1982). Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade, Ada Pharmacol Toxicol (Copenh) 51:321-329.
3. Berridge KC, Robinson TE (1998). What Is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev 28:309-369.
4. Biederman GB, Davey VA (1993). Antisickness conditioning using a nauseaproducing nondrug cue. Behav Neurosci 107:215-217.
5. Bymaster FP, Nelson DL, DeLapp NW, Falcone JF, Eckols K, Truex LL, et al. (1999). Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107-122.
6. Cheng YF, Paalzow LK (1992). Linear pharmacokinetics of haloperidol in the rat. Biopharm Drug Dispos 13:69-76.
7. Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002). Recent trends in anti-psychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 28:75-84.
8. Cole JC, Field M, Sumnall HR, Goudie AJ (2007). Potentiation of olanzapine substitution in rats discriminating clozapine by the D2/3 agonist quinpirole. Behav Pharmacol 18:185-190.
9. Colpaert FC (1986). A method for quantifying state-dependency with chlordia-zepoxide in rats. Psychopharmacology (Berl) 90:144-146.
10. Colpaert F, Koek W, Kleven M, Besnard J (2007). Induction by antipsychotics of win-shift in the drug discrimination paradigm. J Pharmacol Exp Ther 322:288-298.
11. Davey VA, Biederman GB (1991). Methodological issues in drug-drug conditioning in rats: nonassociative factors in heart rate and avfail. Behav Neurosci 105:850-859.
12. Dickinson A, Smith J, Mirenowicz J (2000). Dissociation of Pavlovian and instrumental incentive learning under dopamine antagonists. Behav Neurosci 114:468-483.
13. Fouriezos G, Hansson P, Wise RA (1978). Neuroleptic-induced attenuation of brain stimulation reward in rats. J Comp Physiol Psychol 92:661-671.
14. Goudie A, Taylor A (1998). Comparative characterisation of the discriminative stimulus properties of clozapine and other antipsychotics in rats. Psycho- pharmacology (Berl) 135:392-400.
15. Goudie AJ, Smith JA, Taylor A, Taylor MA, Tricklebank MD (1998). Discriminative stimulus properties of the atypical neuroleptic clozapine in rats: tests with subtype selective receptor ligands. Behav Pharmacol 9:699-710.
16. Goudie AJ, Cooper GD, Cole JC, Sumnall HR (2007). Cyproheptadine resembles clozapine in vivo following both acute and chronic administration in rats. J Psychopharmacol 21:179-190.
17. Joordens RJ, Hijzen TH, Olivier B (1998). The anxiolytic effect on the fear-potentiated startle is not due to a non-specific disruption. Lifesci 63: 2227-2232.
18. Kapur S (2003). Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 160:13-23.
19. Kapur S, Seeman P (2000). Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 25:161-166.
20. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?; a new hypothesis. Am J Psychiatry 158:360-369.
21. Kapur S, Mamo D (2003). Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27:1081-1090.
22. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, Zipursky R (1996). High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry 153:948-950.
23. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN (2003). Antipsychotic dosing in preclinical models Is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631.
24. Keller HH, Schaffner R, Haefely W (1976). Interaction of benzodiazepines with neuroleptics at central dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 294:1-7.
25. Klint T (1991). Effects of 8-OH-DPAT and buspirone in a passive avoidance test and in the elevated plus-maze test in rats. Behav Pharmacol 2:481-489.
26. Koechlin BA, Schwartz MA, Krol G, Oberhansli W (1965). The metabolic fate of C14-labeled chlordiazepoxide in man, in the dog, and in the rat. J Pharmacol Exp Ther 148:399-411.
27. Li M, Parkes J, Fletcher PJ, Kapur S (2004). Evaluation of the motor initiation hypothesis of APD-induced conditioned avoidance decreases. Pharmacol Biochem Behav 78:811-819.
28. Li M, Fletcher PJ, Kapur S (2007). Time course of the antipsychotic effect and the underlying behavioral mechanisms. Neuropsychopharmacology 32:263-272.
29. Li M, He W, Mead A (2009). Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pre-treated rats by selectively weakening motivational salience of conditioned stimulus. Behav Pharmacol 20:84-98.
30. Lieberman JA, Tollefson G, Tohen M, Green Al, Gur RE, Kahn R, et al. (2003). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160:1396-1404.
31. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. W Engl J Med 353:1209-1223.
32. Mead A, Li M. Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism. J Psychopharmacol (in press).
33. Miller R (1987). The time course of neuroleptic therapy for psychosis: role of learning processes and implications for concepts of psychotic illness. Psychopharmacology (Berl) 92:405-415.
34. Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79-104.
35. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S (2006). Dissociation between In vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31:1854-1863.
36. Overton DA (1979). Preclinical measurement of the amount of state-dependent learning produced by psychoactive drugs [proceedings]. Psychopharmacol Bull 15:51-52.
37. Porter JH, McCallum SE, Varvel SA, Vann RE (2000a). The discriminative stimulus properties of the atypical antipsychotic olanzapine in rats. Psychopharmacology (Berl) 148:224-233.
38. Porter JH, Varvel SA, Vann RE, Philibin SD, Wise LE (2000b). Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats. Psychopharmacology (Berl) 149:189-193.
39. Porter JH, Prus AJ, Vann RE, Varvel SA (2005). Discriminative stimulus properties of the atypical antipsychotic clozapine and the typical antipsychotic chlorpromazine in a three-choice drug discrimination procedure in rats. Psychopharmacology (Berl) 178:67-77.
40. Reilly S, Revusky S (1992). Drug-drug heart rate conditioning in rats: effective USs when pentobarbital is the CS. Pharmacol Biochem Behav 42:633-643.
41. Revusky S, Davey V, Zagorski M (1989). Heart rate conditioning with pentobarbital as a conditioned stimulus and amphetamine as an un- conditioned stimulus. Behav Neurosci 103:296-307.
42. Richelson E, Souder T (2000). Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Lifesci 68:29-39.
43. Richtand NM, Welge JA, Logue AD, Keck PE Jr, Strakowski SM, McNamara RK (2007). Dopamine and serotonin receptor binding and antipsychotic efficacy. Neuropsychopharmacology 32:1715-1726.
44. Rupnow MF, Greenspan A, Gharabawi GM, Kosik-Gonzalez C, Zhu Y, Stahl SM (2007). Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. Curr Med Res Opin 23:2815-2822.
45. Sandson NB, Armstrong SC, Cozza KL (2005). An overview of psychotropic drug-drug interactions. Psychosomatics 46:464-494.
46. Sanger DJ (1985). The effects of clozapine on shuttle-box avoidance responding in rats: comparisons with haloperidol and chlordiazepoxide. Pharmacol Biochem Behav 23:231-236.
47. Seeman P (2000). Antipsychotic drugs, dopamine D2 receptors and schizo-phrenia. In: Lidow MS, editor. Neurotransmitter receptors in actions of antipsychotic medications. Boca Raton, Florida: CRC Press LLC; pp. 43-63.
48. Seeman P (2006). Targeting the dopamine D2 receptor in schizophrenia. Expert Opin Ther Targets 10:515-531.
49. Siris SG (1994). Schizophrenia. In: Hirsch SR, Weinberger DR, editors. Schizophrenia: exploring the spectrum of psychosis. Oxford: Blackwell; pp. 128-145.
50. Taukulis HK (1996). Pavlovian conditioning to a diazepam cue with yohimbine as the unconditional stimulus. Neurobiol Learn Mem 65:223-232.
51. Taukulis HK, Brake LD (1989). Therapeutic and hypothermic properties of diazepam altered by a diazepam-chlorpromazine association. Pharmacol Biochem Behav 34:1-6.
52. Taukulis HK, Fillmore MT, Ruggles JL (1992). Neuroleptic-induced changes in the anxiolytic and myorelaxant properties of diazepam In the rat. Pharmacol Biochem Behav 41:13-21.
53. Wadenberg ML, Soliman A, VanderSpek SC, Kapur S (2001). Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of anti-psychotics and their clinical effects. Neuropsychopharmacology 25:633-641.
54. Wilkin LD, Cunningham CL, Fitzgerald RD (1982). Pavlovian conditioning with ethanol and lithium: effects on heart rate and taste aversion in rats. J Comp Physiol Psychol 96:781-790.
55. Wise RA (2004). Dopamine, learning and motivation. Nat Rev Neurosci 5:483-494.
56. Wolkowitz OM, Breler A, Doran A, Lucas P, Kelsoe J, Paul SM, Pickar D (1989). Alprazolam augmentation of neuroleptics in schizophrenia. Am J Psychiatry 146:1087-1088.
57. Zumbrunnen TL, Jann MW (1998). Drug interactions with antipsychotic agents: incidence and therapeutic implications. CNS Drugs 9:381-401.